eCommons@AKU
Section of Internal Medicine

Department of Medicine

9-2019

Risk factors for mortality of patients with ceftriaxone resistant E.
coli bacteremia receiving carbapenem versus beta lactam/beta
lactamase inhibitor therapy
Nosheen Nasir
Sara Ahmed
, Samrah Razi
Safia Awan
Syed Faisal Mahmood

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_intern_med
Part of the Internal Medicine Commons

(2019) 12:611
Nasir et al. BMC Res Notes
https://doi.org/10.1186/s13104-019-4648-7

BMC Research Notes
Open Access

RESEARCH NOTE

Risk factors for mortality of patients
with ceftriaxone resistant E. coli bacteremia
receiving carbapenem versus beta lactam/beta
lactamase inhibitor therapy
Nosheen Nasir1* , Sara Ahmed3, Samrah Razi2, Safia Awan3 and Syed Faisal Mahmood1

Abstract
Objective: Extended spectrum β-lactamases (ESBL) producing Enterobacteriaceae predominantly E. coli and K. pneumoniae bacteremia have limited treatment options and high mortality. The objective was to determine the risk factors
for in-hospital mortality particularly treatment with carbapenem versus beta lactam/beta lactamase combination (BL/
BLI) in patients with ceftriaxone resistant E. coli bacteremia. A retrospective cohort study was conducted at the Aga
Khan University, Karachi, Pakistan. Adult patients with sepsis and monomicrobial ceftriaxone resistant E. coli bacteremia were enrolled. Factors associated with mortality in patients were determined using logistic regression analysis.
Results: Mortality rate was 37% in those empirically treated with carbapenem compared to 20% treated with BL/BLI
combination therapy (p-value: 0.012) and was 21% in those treated with a carbapenem compared to 13% in patients
definitively treated with BL/BLI combination therapy (p-value: 0.152). In multivariable logistic regression analysis, only
Pitt bacteremia score of ≥ four was significantly associated with mortality (OR: 7.7 CI 2.6–22.8) while a urinary source
of bacteremia was protective (OR: 0.26 CI 0.11–0.58). In-hospital mortality in patients with Ceftriaxone resistant E. coli
bacteremia did not differ in patients treated with either a carbapenem or BL/BLI combination. However, Pitt bacteremia score of ≥ 4 was strongly associated with mortality.
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Introduction
Escherichia coli is a leading cause of intra-abdominal,
urinary tract, and bloodstream infections encountered in routine clinical practice [1]. It is a recognized
pathogen for causing both community acquired and
nosocomially acquired infections [1, 2]. Over the past
two decades, antibiotic-resistant strains that produce
extended spectrum β-lactamases (ESBL) have emerged
among the Enterobacteriaceae, predominantly in E. coli
and Klebsiella pneumoniae [2–4]. ESBLs are a group of
hydrolyzing enzymes that provide resistance to third generation cephalosporins and aztreonam, but can in turn be
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hydrolyzed by clavulanic acid [5]. Several epidemiological studies have investigated the prevalence of ESBLs and
their clinical impact [2, 3, 6]. There is considerable geographic variability in the prevalence of ESBLs with the
prevalence being highest in from Latin America and Asia
Pacific region followed by Europe and North America [4].
In a recently conducted meta-analysis from Pakistan, the
pooled prevalence of ESBL producing Enterobacteriaceae
was reported to be 40% [7]. This is similar to proportions
reported from neighbouring countries of China [8] and
India [9] and considerably higher than US and developed
countries from Europe [5]. Hence, Pakistan is a country with high endemicity of community acquired ESBL
producing Enterobacteriaceae with major public health
implications [10, 11].
Since ESBL-producing organisms are frequently resistant to multiple antimicrobial agents therapeutic options
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for these infections are severely limited [12]. Moreover infections caused by ESBL producing organisms
have been associated with high morbidity and mortality
[13]. Studies have shown high Pitt bacteremia score and
Charlson co-morbidity index to be predictive of death
in patients with sepsis secondary to ESBL producing
organisms [14]. Bacteremia with ESBL producing organisms has been associated with a delay in the initiation of
appropriate treatment regimens and leads to an increase
in the hospital length of stay and cost of overall treatment
[14, 15]. Carbapenems have been considered as drugs
of choice for treating severe infections caused by ESBL
producing Enterobacteriaceae as they are not affected
by ESBLs in vitro and clinical efficacy has been demonstrated in several observational studies as well as clinical
trials [5, 16, 17]. A large multi-country open label noninferiority randomized controlled (MERINO) trial which
compared piperacillin tazobactam with meropenem as
definitive treatment for Ceftriaxone resistant E. coli or
K. pneumoniae bloodstream infection found significantly
higher long term mortality in patients randomized to
piperacillin tazobactam arm [16]. However, prolonged
use of carbapenems places the community at risk of
development of carbapenem resistance due to antibiotic
selection pressure [18]. Thus it is imperative to find alternatives for treatment. Beta lactam/beta lactam inhibitor combinations (BL/BLI) have been widely studied
both as empiric and definitive choice of antibiotics and
while some studies have reported no difference in clinical outcomes with use of BL/BLI combination compared
to carbapenem [19]; pooled data from meta-analysis have
recommended their use for only clinically stable patients
with urinary tract infections as the source [17].
Existing studies from Pakistan have shown that ESBL
producing strains of Enterobacteriaceae show greater
than 90 percent susceptibility for BL/BLI and hence may
be an effective alternative [10, 11]. Carbapenem use has
severe cost constraints in a low middle country like Pakistan and is reserved for very severe infections. Despite
the high endemicity of ESBL producing organisms, data
on risk factors for mortality and the optimal choice of
antibiotic therapy is lacking. Our study aims to determine the risk factors for in-hospital mortality in patients
with ESBL E. coli bacteremia using ceftriaxone resistance
as a marker of ESBL presence; with emphasis on difference in outcome when patients were treated with a carbapenem compared to beta lactam/beta lactam inhibitor
combination at a tertiary care hospital in Pakistan.

Main text
Methods

A retrospective cohort study was conducted at the Aga
Khan University (AKU) Hospital in Karachi, Pakistan on
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patients admitted between January 2015 to December
2017. All adult patients with age greater than or equal to
18 years admitted with sepsis (based on established criteria) [20] and found to have monomicrobial ceftriaxone
resistant E. coli bacteremia were included in the study.
Patients were identified from the hospital information
management system.
Data collected from medical records for all patients
included age, sex, nosocomial or community-onset acquisition, type and severity of underlying conditions using
the Charlson comorbidity index, source of bloodstream
infection (BSI) according to clinical and microbiological
data, Pitt bacteremia score, antimicrobial therapy, in-hospital mortality, and length of stay after BSI. The outcome
measure was ‘In-hospital mortality’ and was defined
as death due to all causes during same hospitalization.
Antimicrobial therapy administered before susceptibility
results were available was considered empirical and therapy administered afterwards was considered definitive.
Frequency and percentages were used to describe categorical variables and comparison between variables was
determined using Chi square test or Fischer exact test
where appropriate. p-value of < 0.05 was considered significant. Univariable analyses were performed to examine
the effect of each variable on the in-hospital mortality. In
univariable analysis; p-value < 0.15 was used as the level
of significance in order not to exclude important variables
from the model. Odds ratios (OR) and their 95% confidence intervals (CI) were estimated using logistic regression, with in-hospital mortality as an outcome. Data was
analyzed using SPSS version 16.0.
This study was conducted after receiving exemption
from ethical approval from Aga Khan University Ethical
Review Committee (2734-MED-ERC-13).
Results

Out of a total of the 295 patients that were included, 47%
were males while 53% were females. The mean age of
the patients was 57.71 years (SD: 17.16): Of the patients
who died, the mean age was 55.3 years (SD: 17.9) years
compared to 60.1 (SD: 16.5) years for those who survived (p-value: 0.046). The overall in-hospital mortality in
patients with Ceftriaxone resistant E. coli bacteremia was
21%. The mean length of stay was 11.3 days (SD: 12.5) in
those who died compared to 6.8 days (SD: 5.68) in those
who survived (p-value < 0.001) (Table 1).
In the univariate analysis to determine association
between choice of empirical treatment and mortality;
out of 60 patients who died, n = 20 had received a carbapenem and n = 31 had received a BL/BLI combination therapy. Mortality rate was 37% in those treated
with carbapenem compared to 20% in patients empirically treated with BL/BLI combination therapy (p-value:
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Table 1 Comparison of demographics and clinical features of patients with ceftriaxone resistant E. coli bacteremia who
died compared to those who survived
Patient characteristics

Died (n = 62)

Recovered (n = 235)

Age (mean ± SD)

55.28 ± 17.87

60.14 ± 16.46

0.046

Male

34

106

0.172

Female

28

129

Gender

p-value

Charlson comorbidity index (CCI), mean (SD)

2.98 (2.12)

1.93 (1.73)

< 0.001

Pitt bacteremia score, median (IQR)

3 (4)

1 (2)

< 0.001
< 0.001

Site of infection
Intra-abdominal

24

44

UTI

24

171

CLABSI

4

4

Gut translocation

4

5

Source unclear

6

11

Carbapenem

20

33

BL/BLI

31

121

Carbapenem

36

138

BL/BLI

12

77

11.27 ± 12.46

6.82 ± 5.68

Empirical antibioticsa

0.012

Definitive antibioticsb

Length of stay (mean ± SD)

0.152
< 0.001

a

Empirical group includes only those patients who had been given either a carbapenem or BL/BLI combination treatment empirically

b

Definitive group includes only those patients who had been given either a carbapenem or BL/BLI combination treatment as definitive treatment

0.012). For definitive treatment; n = 36 received a carbapenem whereas n = 21 received BL/BLI combination
therapy among those who died. Mortality rate was 21%
in those treated with a carbapenem compared to 13% in
patients definitively treated with BL/BLI combination
therapy (p-value: 0.152). Other variables found to be significantly associated with mortality included increasing
mean Charlson comorbidity index and increasing Pitt
bacteremia score (Table 1).
However, in multivariable logistic regression analysis;
a Pitt bacteremia score of greater than or equal to 4 was
significantly associated with mortality (OR: 16.8 CI 7.47–
38.0) while presence of urinary tract infection being the
source of bacteremia was protective (OR: 0.33 (CI 0.15–
0.73)) after adjusting for confounding from Charlson
comorbidity index of greater than or equal to 3 (Table 2).
Neither the empirical nor definitive antibiotic therapy
with carbapenem versus BL/BLI combination therapy
was significantly associated with in-hospital mortality.
Discussion

Empiric and definitive choice of antimicrobial therapy
for ESBL producing Enterobacteriaceae has been subject
of debate since a long time because of the implications
of using carbapenem for ESBL infections which while
effective has the potential for promoting carbapenem

Table 2 Multivariable analysis showing factors associated
with in-hospital mortality in patients with Ceftriaxone
resistant E. coli bacteremia
Variables

aOdd ratio (95% CI)

p-value

< 4 (Ref )

1.0

< 0.001

≥4

16.85 (7.47–38.0)

Pitt bacteremia score

Source of infection
Intra-abdominal (Ref )

1.0

0.002

Urinary tract infection

0.33 (0.15–0.73)

0.006

CLABSI

3.03 (0.62–14.66)

0.16

Gut translocation

2.97 (0.50–17.43)

0.22

Source unclear

1.07 (0.28–4.03)

0.91

< 3 (Ref )

1.0

0.055

≥3

1.98 (0.98–3.97)

Charlson comorbidity index score

resistance [18]. Our study did not show an association
of mortality with use of either a carbapenem or a BL/
BLI combination treatment in ceftriaxone resistant E.
coli bacteremia whether it was used empirically or definitively. These findings are similar to a post hoc analysis of
prospective cohort conducted by Rodriguez-Bano et al.
[19] where neither carbapenem nor BL/BLI combination
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influenced mortality or hospital length of stay. However, the recently conducted multi-country open label
non-inferiority randomized controlled (MERINO) trial
which compared piperacillin tazobactam with meropenem as definitive treatment for Ceftriaxone resistant
E. coli or K. pneumoniae bloodstream infection found
significantly higher long term mortality in patients randomized to piperacillin tazobactam arm and concluded
that piperacillin tazobactam was not non-inferior (risk
difference: 8.6%; p = 0.90). The authors therefore recommended avoiding use of this combination for Ceftriaxone resistant bloodstream infections [16]. However,
the trial had several limitations owing to its pragmatic
design with crossover in both arms and that the cause of
30-day mortality was unrelated to infection. Despite the
criticism, the results were quite robust for the conclusion [21]. Given the conclusion of this trial, the concern
for increased carbapenem resistance with increasing use
has left many experts to consider piperacillin tazobactam
for less severe infections with ESBL producing enterobacteriaceae [21]. Despite this, similar to the MERINO
trial, our study showed that the short-term outcomes (i.e.
inpatient mortality) is similar for both carbapenems and
BL/BLI combinations in ceftriaxone resistant Enterobacteriaceae. Our study was however not designed to look at
the long term effects between the two regimens, including the outcomes post discharge. As for other comparisons between both antibiotics as empirical therapy, there
has been a systematic review and meta-analysis of nonrandomized studies which concluded that carbapenems
should be given preference as drug of choice in patients
with ESBL-producing Enterobacteriaceae bloodstream
infections [17]. However, there was substantial clinical and statistical heterogeneity in the studies included
in this review and a more recent review conducted by
Sfeir et al. [22] in 2018 have not found any difference in
30-day mortality with use of either carbapenem or BL/
BLI combination. Comparison studies for appropriate
choice of antibiotic for ESBL producing Enterobacteriaceae bacteremia are lacking from South Asian region
which differs from the west in terms of geographical and
economic diversity. A resource poor country like ours
where carbapenem use has severe cost implications and
is considered to be one of the last resort antibiotics, it is
imperative to determine which antibiotic is better and we
recommend future randomized controlled trials in this
region based on our results.
Several predictors of mortality; apart from choice of
antibiotics; have been identified in various studies for
ESBL Enterobacteriaceae bloodstream infections. These
include high Charlson comorbidity index, high Pitt bacteremia scores and source of bloodstream infection other
than urinary tract [13, 14, 23]. In our study also we found

Page 4 of 5

significant association of Pitt bacteremia score of greater
than 4 to be significantly associated with in-hospital mortality in patients with ceftriaxone resistant E. coli bacteremia. Moreover, similar to findings of other studies,
presence of urinary tract infection was favourable.
Conclusion

In conclusion, our study shows that there was no difference in in-hospital mortality in patients with ceftriaxone
resistant E. coli bacteremia in patients treated with either
a carbapenem or BL/BLI combination whether empirically or definitively. However, Pitt bacteremia score of
greater than or equal to 4 was strongly associated with
mortality while urinary tract as site of infection was protective. We recommend randomized controlled trials for
further delineating choice of appropriate antibiotic in our
resource poor region.

Limitations
There are several limitations of our study. Firstly, we have
used Ceftriaxone resistance as a marker of ESBL presence
and we do not have genotypic and MIC data for our isolates. However, the study is intended to guide in real life
scenarios encountered in clinical practice in our setting
where molecular studies are not widely available. Moreover, large pragmatic trial has also utilized ceftriaxone
resistance as surrogate marker for better feasibility [16].
Secondly, our study is a single center study and hence the
generalizability may be limited to our region. Similarly,
the lack of difference in mortality, especially between the
two treatment regimens, may have been due to the small
sample size.
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